Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Cash Flow Conversion Efficiency

Latest as of June 2023: -0.010x

Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-64.53 Million ≈ $-75.45 Million USD) by net assets (€6.39 Billion ≈ $7.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Tianjin Zhong Xin Pharmaceutical Group C to measure how many days the company can operate on defensive assets alone.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bank of Kaohsiung Ltd TW:2836	-0.099x
Goldcard High-Tech Co Ltd SHE:300349	0.047x
QITIAN Technology Group Co Ltd SHE:300061	-0.191x
Logistea AB Series B ST:LOGI-B	0.003x
Diagnósticos da América S.A SA:DASA3	0.055x
Cannae Holdings Inc NYSE:CNNE	-0.018x
Collins Foods Ltd AU:CKF	0.166x
Sunyard System Engineering Co Ltd SHG:600571	-0.078x

Annual Cash Flow Conversion Efficiency for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2025)

The table below shows the annual cash flow conversion efficiency of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Tianjin Zhong Xin Pharmaceutical Group C stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€7.10 Billion ≈ $8.30 Billion	€461.07 Million ≈ $539.03 Million	0.065x	-44.87%
2024-12-31	€7.85 Billion ≈ $9.18 Billion	€924.67 Million ≈ $1.08 Billion	0.118x	+13.69%
2023-12-31	€6.65 Billion ≈ $7.77 Billion	€688.49 Million ≈ $804.91 Million	0.104x	+0.23%
2022-12-31	€6.55 Billion ≈ $7.66 Billion	€677.25 Million ≈ $791.77 Million	0.103x	-21.01%
2021-12-31	€6.51 Billion ≈ $7.62 Billion	€852.40 Million ≈ $996.55 Million	0.131x	+15.96%
2020-12-31	€5.95 Billion ≈ $6.96 Billion	€671.42 Million ≈ $784.96 Million	0.113x	+25.79%
2019-12-31	€5.52 Billion ≈ $6.46 Billion	€495.49 Million ≈ $579.28 Million	0.090x	+29.50%
2018-12-31	€5.05 Billion ≈ $5.91 Billion	€350.14 Million ≈ $409.36 Million	0.069x	+8165.98%
2017-12-31	€4.63 Billion ≈ $5.41 Billion	€-3.97 Million ≈ $-4.64 Million	-0.001x	-100.88%
2016-12-31	€4.30 Billion ≈ $5.03 Billion	€417.77 Million ≈ $488.42 Million	0.097x	+10.55%
2015-12-31	€4.11 Billion ≈ $4.80 Billion	€360.58 Million ≈ $421.56 Million	0.088x	-9.77%
2014-12-31	€2.95 Billion ≈ $3.44 Billion	€286.85 Million ≈ $335.36 Million	0.097x	+17.45%
2013-12-31	€2.57 Billion ≈ $3.01 Billion	€213.44 Million ≈ $249.53 Million	0.083x	--

About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited

STU:2TZ Germany Drug Manufacturers - Specialty & Generic

Market Cap

$692.11 Million

€592.00 Million EUR

Market Cap Rank

#10658 Global

#1244 in Germany

Share Price

€2.96

Change (1 day)

+8.82%

52-Week Range

€2.04 - €3.15

All Time High

€3.15